A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy
Clinical trial NCT06156332 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06156332
- Sponsor
- Shanghai Changzheng Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-28
- Primary completion
- 2025-01-28
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.